CN1038587C - 1,4－二氢吡啶衍生物的制备方法 - Google Patents

1,4－二氢吡啶衍生物的制备方法 Download PDF

Info

Publication number
CN1038587C
CN1038587C CN88106537A CN88106537A CN1038587C CN 1038587 C CN1038587 C CN 1038587C CN 88106537 A CN88106537 A CN 88106537A CN 88106537 A CN88106537 A CN 88106537A CN 1038587 C CN1038587 C CN 1038587C
Authority
CN
China
Prior art keywords
methyl
amino
ethyl
formula
phenyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN88106537A
Other languages
English (en)
Chinese (zh)
Other versions
CN1031531A (zh
Inventor
卡洛斯·费尔南德斯托里哈
约阿昆·阿尔瓦罗加利亚诺拉莫斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmaceutical Manufacturing Co Ltd
Laboratoires Delagrange SA
Original Assignee
Pharmaceutical Manufacturing Co Ltd
Laboratoires Delagrange SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaceutical Manufacturing Co Ltd, Laboratoires Delagrange SA filed Critical Pharmaceutical Manufacturing Co Ltd
Publication of CN1031531A publication Critical patent/CN1031531A/zh
Application granted granted Critical
Publication of CN1038587C publication Critical patent/CN1038587C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN88106537A 1987-08-03 1988-08-02 1,4－二氢吡啶衍生物的制备方法 Expired - Fee Related CN1038587C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP87401799.9 1987-08-03
EP87401799A EP0302980B1 (fr) 1987-08-03 1987-08-03 1,4-Dihydropyridines, leur procédé de préparation et leur application comme médicaments

Publications (2)

Publication Number Publication Date
CN1031531A CN1031531A (zh) 1989-03-08
CN1038587C true CN1038587C (zh) 1998-06-03

Family

ID=8198243

Family Applications (1)

Application Number Title Priority Date Filing Date
CN88106537A Expired - Fee Related CN1038587C (zh) 1987-08-03 1988-08-02 1,4－二氢吡啶衍生物的制备方法

Country Status (34)

Country Link
US (1) US4952592A (enExample)
EP (1) EP0302980B1 (enExample)
JP (1) JPH0733383B2 (enExample)
KR (1) KR960001724B1 (enExample)
CN (1) CN1038587C (enExample)
AT (1) ATE61588T1 (enExample)
BE (1) BE1001055A4 (enExample)
CA (2) CA1306261C (enExample)
CH (1) CH675999A5 (enExample)
CZ (1) CZ282077B6 (enExample)
DD (1) DD282008A5 (enExample)
DE (2) DE3768658D1 (enExample)
DK (1) DK430288A (enExample)
ES (1) ES2007543A6 (enExample)
FI (1) FI91406C (enExample)
GB (1) GB2208861B (enExample)
GR (2) GR880100507A (enExample)
HU (1) HU204523B (enExample)
IE (1) IE60358B1 (enExample)
IL (1) IL87321A (enExample)
IN (1) IN167550B (enExample)
IS (1) IS1549B (enExample)
IT (1) IT1235013B (enExample)
LU (1) LU87297A1 (enExample)
MA (1) MA21344A1 (enExample)
NO (1) NO170934C (enExample)
NZ (1) NZ225661A (enExample)
PH (1) PH25645A (enExample)
PT (1) PT88173B (enExample)
RU (1) RU2036922C1 (enExample)
SK (1) SK278775B6 (enExample)
TN (1) TNSN88081A1 (enExample)
YU (1) YU46547B (enExample)
ZA (1) ZA885684B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242933A (en) * 1990-07-10 1993-09-07 Adir Et Compagnie Piperidine, tetrahydropyridine and pyrrolidine compounds
WO1997004781A1 (en) * 1995-08-02 1997-02-13 Smithkline Beecham Corporation Endothelin receptor antagonists
RU2168987C2 (ru) * 1997-04-15 2001-06-20 Санкт-Петербургская Государственная Химико-Фармацевтическая Академия Гипотензивное средство
RU2155036C2 (ru) * 1998-11-11 2000-08-27 Азад Зияд Оглы Абышев Средство для лечения ишемической болезни сердца
IT1304513B1 (it) * 1998-12-30 2001-03-19 Endura Spa Processo per la sintesi di 5-(alfa-idrossialchil)benzo(1,3)diossoli.
BR0109991A (pt) * 2000-04-11 2003-05-27 Sankyo Co Composição farmacêutica
RU2187303C2 (ru) * 2000-10-12 2002-08-20 Азад Зияд Оглы Абышев Способ получения таблеток диуманкала - forte по 0,01 г
EA200500234A1 (ru) 2002-08-19 2005-08-25 Пфайзер Продактс Инк. Комбинированная терапия гиперпролиферативных болезней
CA2574958A1 (en) * 2004-07-26 2006-02-09 Cotherix, Inc. Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
EP2351569B1 (en) 2005-10-26 2012-08-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
WO2007050783A2 (en) 2005-10-26 2007-05-03 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
TW200736245A (en) * 2005-11-29 2007-10-01 Sankyo Co Acid addition salts of optically active dihydropyridine derivatives
TW200806648A (en) * 2005-11-29 2008-02-01 Sankyo Co Acid addition salts of dihydropyridine derivatives
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
WO2012037665A1 (en) 2010-09-24 2012-03-29 Oral Delivery Technology Ltd. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
CN105143203A (zh) 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3441648A (en) * 1967-02-07 1969-04-29 Smithkline Corp Compositions and methods for lowering blood pressure with 1,4-dihydropyridines
US4031104A (en) * 1972-04-18 1977-06-21 Bayer Aktiengesellschaft 1,4-Dihydropyridine carboxylic acid esters
JPS5978186A (ja) * 1982-10-27 1984-05-04 Yoshitomi Pharmaceut Ind Ltd １，４−ジヒドロピリジン−３，５−ジカルボン酸エステル誘導体
ES531033A0 (es) * 1984-03-27 1985-09-01 Inst Investigacion Desarrollo Un procedimiento para la preparacion de nuevas 1,4-dihidropirinas-4-(polioxialquilfenil)-sustituidas
IE57810B1 (en) * 1984-03-27 1993-04-21 Delagrange Lab 1,4-dihydropyridine derivatives,their preparation and their use
JPH068294B2 (ja) * 1985-02-26 1994-02-02 富山化学工業株式会社 新規な１，４−ジヒドロピリジン誘導体およびその塩
EP0174131A3 (en) * 1984-09-01 1989-06-07 FISONS plc Dihydropyridines, processes and intermediates for their production, and pharmaceutical formulations containing them
JPH01207267A (ja) * 1987-03-05 1989-08-21 Yamanouchi Pharmaceut Co Ltd ピリジン誘導体及び該化合物を含有する肝疾患治療剤

Also Published As

Publication number Publication date
IE882364L (en) 1989-02-03
HU204523B (en) 1992-01-28
YU147088A (en) 1990-04-30
IT8848259A0 (it) 1988-08-02
JPH0733383B2 (ja) 1995-04-12
IT1235013B (it) 1992-06-16
PH25645A (en) 1991-08-21
YU46547B (sh) 1993-11-16
GR880100507A (el) 1989-05-25
US4952592A (en) 1990-08-28
KR890003743A (ko) 1989-04-17
CN1031531A (zh) 1989-03-08
JPH01294675A (ja) 1989-11-28
IN167550B (enExample) 1990-11-10
CZ282077B6 (cs) 1997-05-14
AU606441B2 (en) 1991-02-07
IL87321A0 (en) 1989-01-31
HUT54142A (en) 1991-01-28
GB2208861B (en) 1991-07-17
LU87297A1 (fr) 1989-02-02
EP0302980A1 (fr) 1989-02-15
IS3378A7 (is) 1989-02-04
FI91406C (fi) 1994-06-27
FI883603A7 (fi) 1989-02-04
TNSN88081A1 (fr) 1990-07-10
CA1306262C (fr) 1992-08-11
DD282008A5 (de) 1990-08-29
GR3001984T3 (en) 1992-11-23
IS1549B (is) 1994-06-08
DK430288D0 (da) 1988-08-02
FI91406B (fi) 1994-03-15
PT88173A (pt) 1989-06-30
KR960001724B1 (ko) 1996-02-03
DE3768658D1 (de) 1991-04-18
NO170934B (no) 1992-09-21
RU2036922C1 (ru) 1995-06-09
SK541388A3 (en) 1998-02-04
ZA885684B (en) 1989-04-26
DE3825962A1 (de) 1989-02-16
NO883406L (no) 1989-02-06
IL87321A (en) 1993-04-04
CA1306261C (fr) 1992-08-11
MA21344A1 (fr) 1989-04-01
CH675999A5 (en) 1990-11-30
BE1001055A4 (fr) 1989-06-20
ATE61588T1 (de) 1991-03-15
DK430288A (da) 1989-02-03
CZ541388A3 (en) 1997-01-15
AU2033088A (en) 1989-02-09
GB8818356D0 (en) 1988-09-07
EP0302980B1 (fr) 1991-03-13
NO883406D0 (no) 1988-08-01
IE60358B1 (en) 1994-06-29
NZ225661A (en) 1990-08-28
FI883603A0 (fi) 1988-08-01
SK278775B6 (sk) 1998-02-04
GB2208861A (en) 1989-04-19
NO170934C (no) 1992-12-30
PT88173B (pt) 1995-03-01
ES2007543A6 (es) 1989-06-16

Similar Documents

Publication Publication Date Title
CN1163484C (zh) 4-芳酰基-哌啶-ccr-3受体拮抗剂ⅲ
CN1159311C (zh) 二氢嘧啶类化合物
CN1025999C (zh) 咪唑并[4，5-b]喹啉氧烷酰胺的制备方法
CN1153765C (zh) 具有神经营养和保护活性的4-芳基-1-苯基烷基-1,2,3,6-四氢吡啶
CN1560035A (zh) 5－羟基吲哚－3－羧酸脂类衍生物
CN1031531A (zh) 1，4-二氢吡啶其制备方法及其用于药品的用途
CN1017897B (zh) 二氢吡啶衍生物的制备方法
CN1305464A (zh) 杂环化合物和治疗心力衰竭及其它疾病的方法
CN86107595A (zh) 新的药物化合物
CN1014409B (zh) 生产抗坏血酸衍生物的方法
CN1018614B (zh) 制备含n-杂环基-4-哌啶胺类的抗组胺组合物的方法
CN86106242A (zh) 2-硫代甲基-取代-1，4-二氢吡啶，其制造方法和含有这些化合物的药物组合物
CN1745065A (zh) 4－氧代－3－(1－氧代－1h－异喹啉－2－基乙酰氨基)－戊酸酯和酰胺衍生物及其作为天冬氨酸特异性半胱氨酸蛋白酶抑制剂的用途
CN1067892A (zh) 新的吡咯并[2，3-b]吡啶衍生物的制备方法
CN1482118A (zh) 新颖的5－羟基－3－羧酸酯吲哚类衍生物及其制备方法
CN1314345A (zh) 新的哌啶－4－磺酰胺化合物、其制备方法和含有它们的药物组合物
CN1148372C (zh) 具有5－羟色胺－2受体拮抗作用和α1-阻断作用的吡咯噻嗪和吡咯硫杂吖庚因化合物
CN1087737C (zh) 用作缓激肽拮抗剂的二氢吡啶衍生物
CN88101927A (zh) 二氢吡啶酰胺类化合物，其制备方法及医药上的应用
CN1034501C (zh) (二苯甲基乙氧基哌啶基)脂族酸衍生物的制备方法
CN100335464C (zh) 芳烷基－四氢－吡啶,其制备方法及含有它们的药物组合物
CN1076444A (zh) 咪唑基取代的苯乙酰胺
CN1852907A (zh) 2－氨基－5－苯甲酰基噻唑npy拮抗剂
CN1505624A (zh) 哌嗪子基衍生物及其作为pde4抑制剂的用途
CN1100419A (zh) 3-喹啉基取代二氢吡啶类化合物及其制备方法与药用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Madrid, Spain

Applicant after: Laboratories Delagrange

Co-applicant after: Pharmaceutical Co Ltd

Applicant before: Laboratorios Delagrange

Co-applicant before: Laboratories Delagrange

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: LABORATORIOS DELAGRANGE TO: BIOCHEMISTRY, INSTITUTE OF DEVELOPMENT STUDIES CO., LTD.; CO-APPLICANT; FROM: BIOCHEMISTRY, INSTITUTE OF DEVELOPMENT STUDIES CO., LTD. TO: PULLDEASE PHARMACEUTICAL CO., LTD.

C14 Grant of patent or utility model
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Co-applicant after: Almirel Prodis Pharmaceutical Co., Ltd.

Co-applicant before: Pharmaceutical Co Ltd

COR Change of bibliographic data

Free format text: CORRECT: CO-APPLICANT; FROM: PULLDEASE PHARMACEUTICAL CO., LTD. TO: ARLE MIREL-PROTEAS PHARMACEUTICAL CO., LTD.

GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee